108 related articles for article (PubMed ID: 18400122)
1. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
Mühlberger N; Sroczynski G; Esteban E; Mittendorf T; Miksad RA; Siebert U
Int J Technol Assess Health Care; 2008; 24(2):184-92. PubMed ID: 18400122
[TBL] [Abstract][Full Text] [Related]
2. Benefits and costs of using HPV testing to screen for cervical cancer.
Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
Chow IH; Tang CH; You SL; Liao CH; Chu TY; Chen CJ; Chen CA; Pwu RF
Br J Cancer; 2010 Dec; 103(12):1773-82. PubMed ID: 21102588
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
7. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
[TBL] [Abstract][Full Text] [Related]
8. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
[TBL] [Abstract][Full Text] [Related]
9. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.
Kulasingam SL; Rajan R; St Pierre Y; Atwood CV; Myers ER; Franco EL
BMC Med; 2009 Nov; 7():69. PubMed ID: 19900264
[TBL] [Abstract][Full Text] [Related]
11. Cost of screening and treatment of cervical dyskaryosis in Germany.
Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
[TBL] [Abstract][Full Text] [Related]
12. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
13. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
Barré S; Massetti M; Leleu H; De Bels F
BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
Ezat SW; Aljunid S
Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
[No Abstract] [Full Text] [Related]
18. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology.
Cochand-Priollet B; Le Galès C; de Cremoux P; Molinié V; Sastre-Garau X; Vacher-Lavenu MC; Vielh P; Coste J;
Diagn Cytopathol; 2001 Jun; 24(6):412-20. PubMed ID: 11391824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]